

In the Claims:

Please amend claims 1-6, 13-15, and 20; and add new claim 26. A marked-up listing of the entire claims appears below.

1. (currently amended) A hybrid polypeptide comprising at least two different plant allergenic proteins or fragments thereof, wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein.

2. (currently amended) A hybrid polypeptide according to claim 1, wherein the plant hybrid polypeptide comprises at least one complete allergenic protein.

3. (currently amended) A hybrid polypeptide according to claim 2, wherein the plant hybrid polypeptide comprises at least two complete allergenic proteins.

4. (currently amended) A hybrid polypeptide according to claim 1, wherein the plant hybrid polypeptide comprises at least one fragment of an allergenic protein which fragment has a ~~substantially~~ reduced allergenic activity compared with the allergenic protein from which it is derived.

5. (currently amended) A hybrid polypeptide according to claim 4, wherein the plant hybrid polypeptide comprises fragments of at least two different allergenic proteins all of which fragments have a ~~substantially~~ reduced allergenic activity compared with the respective allergenic proteins from which they are derived.

6. (currently amended) A hybrid polypeptide according to claim 1, comprising at least three different plant allergenic proteins or fragments thereof.

7. (withdrawn) A polynucleotide encoding the hybrid polypeptide of claim 1.

8. (canceled)

9. (withdrawn) A cell transfected or transformed with the polynucleotide of claim 7.

10-12. (canceled)

13. (currently amended) A method for preparing a hybrid polypeptide according to claim 1, comprising:

- a) providing a polynucleotide encoding the plant hybrid polypeptide;
- b) introducing said polynucleotide into a host cell;
- c) culturing the host cell obtained in b) under conditions such that the hybrid polypeptide is expressed; and
- d) recovering the expressed plant hybrid polypeptide from the cultured host cell.

14. (currently amended) A method according to claim 13, wherein the polynucleotide encoding the plant hybrid polypeptide is obtained using PCR technology.

15. (currently amended) A method for preparing a plant hybrid polypeptide according to claim 1, wherein the plant hybrid polypeptide is prepared by chemical synthesis.

16 – 19. (canceled)

20. (currently amended) A pharmaceutical composition comprising the plant hybrid polypeptide of claim 1, ~~the polynucleotide of claim 7 or the cell of claim 9.~~

21. (previously presented) A pharmaceutical composition according to claim 20, further comprising an adjuvant.

22. (withdrawn) A method for treating an allergic disorder comprising administering the pharmaceutical composition of claim 20 to a patient in need thereof.

23. (withdrawn) A method for inducing tolerance to a given allergen, comprising administering the pharmaceutical composition of claim 20 to a patient in need thereof.

24. (withdrawn) A method for providing immunity to a given allergen, comprising administering the pharmaceutical composition of claim 20 to a patient in need thereof.

25. (withdrawn) A method for detecting antibodies against a given allergenic protein in a sample, comprising conducting *in vitro* antibody tests employing the hybrid polypeptide of any one of claims 1 to 6 or conducting *in vitro* or *in vivo* cellular-based tests employing the hybrid polypeptide of any one of claims 1 to 6.

26. (new) A hybrid polypeptide comprising of at least four different plant allergenic proteins or fragments thereof, wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein.